DHL COLDCHAIN offers fast, reliable and flexible solutions designed for the Life Science Industry

The life science industry increasingly demands for Europe-wide transport solutions which are able to guarantee product integrity. Being able to offer this, strengthens a global market position. Thus, DHL Freight has been developing the unique DHL COLDCHAIN network.

DHL COLDCHAIN supports its customers by efficient, flexible and most reliable transport solutions along the entire supply chain. By shaping this innovative solution across Europe, DHL Freight becomes the preferred logistics partner for the life science industry.

DHL comprises long-term experience and knowledge gathered by working for major life science companies for numerous years.DHL has been constantly listening to its customers in all major layers in the market sector, and learned their specific requirements and demands concerning transport solutions. Following these guidelines the DHL COLDCHAIN services have been developed. DHL COLDCHAIN is a dedicated, fully monitored and temperature controlled LTL network offering the best possible treatment for sensitive products of this market sector.

DHL COLDCHAIN meets all requirements of the industry in terms of temperature control, security and handling. Its services cover the range of refrigerated (2 – 8° Celsius) as well as controlled ambient products (2 – 25° Celsius).

International temperature controlled network
Throughout Europe, DHL Freight built the infrastructure for demanding products of pharmaceutical and life science industry. A fleet of refrigerated trucks is at your disposal at any time, and ensures the sensitive goods are constantly treated at the right temperature.

Throughout the journey, the temperature of the pharmaceuticals is continuously measured and transmitted via GPS.With our state of-the-art IT tools, this allows each customer to track the status and temperature of all shipments during the entire journey. In addition, all warehouses and cross docking stations are specifically equipped to guarantee continuous temperature control. Of course, they meet all GDP requirements (Good Distribution Practice). In the extension of DHL Freight network of branch offices and cross-docking stations, DHL COLDCHAIN provides the shortest possible lead-times. As an advantage, DHL COLDCHAIN is an LTL (less than truck load) service with fixed departure schedules. By these choices, our customers benefit from our flexibility and costeffectiveness. Even for smaller volumes.

Services

  • Unique DHL COLDCHAIN network across Europe and beyond
  • LTL consolidation service
  • Temperature controlled services for refrigerated (2 – 8° Celsius) as well as controlled ambient products (2 – 25° Celsius)
  • Top quality handling and security services
  • GPS security surveillance
  • Scheduled departures and deliveries
  • Short lead times
  • Central booking and administration
  • Online tracking & tracing
  • Temperature data recording

For further information, please contact:

DHL Freight
Life Science Competence Center
DHL Logistics (Switzerland) Ltd
St. Jakobs-Strasse 224
4052 Basle
Switzerland
Telephone +41 61 315 9191
www.dhl.ch

Most Popular Now

Sustained cellular immune dysregulation in individ…

COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, espe...

New virtual screening strategy identifies existing…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, c...

Pfizer and BioNTech to supply the U.S. with 100 mi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the compan...

European Commission authorizes COVID-19 vaccine Mo…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Commission has granted a cond...

An in vitro study shows Pfizer-BioNTech COVID-19 v…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas Medical Branch (UTMB...

Serum Institute of India obtains emergency use aut…

AstraZeneca's COVID-19 vaccine has been granted emergency use authorisation in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the act...

CureVac and Bayer join forces on COVID-19 vaccine …

Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines b...

New findings help explain how COVID-19 overpowers …

Seeking to understand why COVID-19 is able to suppress the body's immune response, new research from the USC Leonard Davis School of Gerontology suggests that mitochondri...

China grants conditional market approval for Sinop…

The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, C...

Novavax announces initiation of PREVENT-19 pivotal…

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVEN...

AstraZeneca's COVID-19 vaccine authorised for emer…

AstraZeneca's COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will supply an additional 100 million doses of COMIRNATY®, the companies' COVID-19 Vaccine, to the 2...